US2012232101A1PendingUtilityA1
Novel Compounds
Est. expiryNov 29, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 9/04A61P 9/00A61P 35/04A61P 43/00A61P 35/00A61P 31/12A61P 9/10A61P 27/02A61P 25/00A61P 25/28A61P 29/00A61P 13/12A61P 1/16A61P 19/02A61P 19/08A61P 11/02A61P 17/00A61P 19/00A61P 1/04A61P 11/06A61P 1/02A61P 11/00A61P 21/00A61P 19/06A61P 15/00C07D 403/12C07D 239/34A61K 31/506
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides compounds of formula (I): wherein R 1 and R 2 are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A compound of formula:
or a pharmaceutically acceptable salt thereof.
20 . A pharmaceutical composition comprising a compound of formula:
or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent, or carrier.
21 . A method of treating aortic aneurysm, which comprises administering to a patient a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.